{"id":44206,"date":"2025-10-23T20:18:06","date_gmt":"2025-10-23T12:18:06","guid":{"rendered":"https:\/\/flcube.com\/?p=44206"},"modified":"2025-10-23T20:18:07","modified_gmt":"2025-10-23T12:18:07","slug":"padcev-yields-60-efs-reduction-in-mibc-astellas%e2%80%91pfizer-ev%e2%80%91303-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44206","title":{"rendered":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study"},"content":{"rendered":"\n<p>Astellas (<a href=\"https:\/\/www.google.com\/finance\/quote\/TSE:NYSE\">TSE: 4503<\/a>) and Pfizer (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a <strong>60\u202f% lower risk of event\u2011free survival (EFS) events<\/strong> in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant <strong>PADCEV (enfortumab vedotin)<\/strong> plus <strong>pembrolizumab<\/strong> versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\"><strong>Key Findings<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EFS Hazard Ratio (HR):<\/strong> 0.40 (95\u202f% CI\u202f0.28\u20110.57; <em>p<\/em>\u202f&lt;\u202f0.0001)<\/li>\n\n\n\n<li><strong>EFS Median:<\/strong> Not reached (combination) vs. 15.7\u202fmonths (surgery)<\/li>\n\n\n\n<li><strong>2\u2011Year EFS:<\/strong> 74.7\u202f% (combination) vs. 39.4\u202f% (surgery)<\/li>\n\n\n\n<li><strong>OS Hazard Ratio:<\/strong> 0.50 (95\u202f% CI\u202f0.33\u20110.76; <em>p<\/em>\u202f&lt;\u202f0.0001)<\/li>\n\n\n\n<li><strong>OS Median:<\/strong> Not reached (combination) vs. 41.7\u202fmonths (surgery)<\/li>\n\n\n\n<li><strong>2\u2011Year OS:<\/strong> 79.7\u202f% (combination) vs. 63.1\u202f% (surgery)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-study-design\"><strong>Study Design<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>PADCEV\u202f+\u202fPembrolizumab (N\u202f=\u202f210)<\/th><th>Surgery Alone (N\u202f=\u202f210)<\/th><\/tr><\/thead><tbody><tr><td>Treatment<\/td><td>15\u202fmg ER q.d. + 200\u202fmg q.o.w.<\/td><td>Standard cystectomy \u00b1 adjuvant<\/td><\/tr><tr><td>Follow\u2011up<\/td><td>24\u202fmonths interim<\/td><td>24\u202fmonths interim<\/td><\/tr><tr><td>Primary Endpoint<\/td><td>EFS (tumor recurrence, progression, or death)<\/td><td>EFS<\/td><\/tr><tr><td>Secondary Endpoint<\/td><td>OS<\/td><td>OS<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile\"><strong>Safety Profile<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment\u2011emergent AEs:<\/strong> 84\u202f% (combination) vs. 79\u202f% (surgery) \u2013 mostly Grade\u202f1\u20112<\/li>\n\n\n\n<li><strong>Grade\u202f\u2265\u202f3 AEs:<\/strong> 23\u202f% (combination) vs. 21\u202f% (surgery) \u2013 manageable<\/li>\n\n\n\n<li><strong>Infusion reactions:<\/strong> &lt;\u202f2\u202f% (combination) \u2013 all Grade\u202f1\u20112<\/li>\n\n\n\n<li><strong>No new safety signals<\/strong> identified relative to prior PADCEV and pembrolizumab data.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-bladder-cancer-therapy\"><strong>Implications for Bladder Cancer Therapy<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class ADC<\/strong>: Enfortumab vedotin targets Nectin\u20114, a protein highly expressed in urothelial carcinoma.<\/li>\n\n\n\n<li><strong>Expanded Indication<\/strong>: The data support PADCEV plus pembrolizumab as a neoadjuvant\/adjuvant strategy for cisplatin\u2011ineligible MIBC patients.<\/li>\n\n\n\n<li><strong>Regulatory Impact<\/strong>: Findings may inform FDA and EMA review for an expanded indication and could accelerate market access in key regions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,353,16,17,863,309,876],"class_list":["post-44206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-astellas-pharma","tag-cancer","tag-clinical-trial-results","tag-nyse-pfe","tag-pfizer","tag-tse-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44206\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study\" \/>\n<meta property=\"og:description\" content=\"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44206\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T12:18:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T12:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study\",\"datePublished\":\"2025-10-23T12:18:06+00:00\",\"dateModified\":\"2025-10-23T12:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2305.webp\",\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"Astellas Pharma\",\"Cancer\",\"Clinical trial results\",\"NYSE: PFE\",\"Pfizer\",\"TSE: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44206#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44206\",\"name\":\"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2305.webp\",\"datePublished\":\"2025-10-23T12:18:06+00:00\",\"dateModified\":\"2025-10-23T12:18:07+00:00\",\"description\":\"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\\\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44206\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2305.webp\",\"width\":1080,\"height\":608,\"caption\":\"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44206#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44206","og_locale":"en_US","og_type":"article","og_title":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study","og_description":"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.","og_url":"https:\/\/flcube.com\/?p=44206","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-23T12:18:06+00:00","article_modified_time":"2025-10-23T12:18:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44206#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44206"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study","datePublished":"2025-10-23T12:18:06+00:00","dateModified":"2025-10-23T12:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44206"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","keywords":["Academic conference","ADC \/ XDC","Astellas Pharma","Cancer","Clinical trial results","NYSE: PFE","Pfizer","TSE: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44206#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44206","url":"https:\/\/flcube.com\/?p=44206","name":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44206#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44206#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","datePublished":"2025-10-23T12:18:06+00:00","dateModified":"2025-10-23T12:18:07+00:00","description":"Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase\u202fIII EV\u2011303 (KEYNOTE\u2011905) trial demonstrated a 60\u202f% lower risk of event\u2011free survival (EFS) events in patients with muscle\u2011invasive bladder cancer (MIBC) who received neoadjuvant\/adjuvant PADCEV (enfortumab vedotin) plus pembrolizumab versus surgery alone. The interim analysis, presented at the 2025 European Society for Medical Oncology (ESMO) Congress, also showed a 50\u202f% reduction in death risk and a 79.7\u202f% 2\u2011year overall survival (OS) rate in the combination arm.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44206#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44206"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44206#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","width":1080,"height":608,"caption":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44206#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PADCEV Yields 60\u202f% EFS Reduction in MIBC \u2013 Astellas\u2011Pfizer EV\u2011303 Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44206"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44206\/revisions"}],"predecessor-version":[{"id":44209,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44206\/revisions\/44209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44208"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}